Drug Burden Index is Associated With Malnutrition in Community-dwelling Dementia Patients
NCT ID: NCT06447259
Last Updated: 2024-06-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
415 participants
OBSERVATIONAL
2023-05-20
2023-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A total of 415 outpatients with dementia, evaluated by Mini Nutrition Assessment test and registered drug information, are included in the study. The investigator calculated the DBI as the sum of all sedatives and anticholinergics taken continuously for at least four weeks prior to admission and evaluated the ACB score.
Practice Impact: Due to accompanying chronic diseases and symptoms, cholinergic and/or sedative-loaded drugs are often prescribed to dementia patients. In this study, İnvestigators emphasized that in addition to the cholinergic loads of the drugs used, their sedative loads and the drug doses they use are also important. Avoiding prescribing these medications to patients with dementia will protect them from malnutrition and its negative consequences.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prevalence of Anticholinergics in Geriatric Patients With Acute Functional Deterioration
NCT07165574
Effectiveness of Dementia Nutrition Education
NCT06739642
Assessment of DeMentia Nutrition Intervention Needs Among Care Recipients and carEgivers
NCT05536830
Nutraceuticals and Drug Treatment in Frail Older Adults
NCT04962841
Persons With Dementia and Their Extended Family Caregivers
NCT04863859
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be able to swallow tablets
* Must be recorded data of medications and doses
Exclusion Criteria
* Mild cognitive impairment
* End-stage diseases (renal, liver, cardiac)
* Uncontrolled thyroid functions
65 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sultan Keskin Demircan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sultan Keskin Demircan
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sultan Keskin Demircan
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GulhaneTR2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.